 |
The Lattice (Official 3DHEALS Podcast)Author: 3DHEALS
Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 3DHEALS Links: https://linktr.ee/3dheals DisclaimerThe content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations.While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement.This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings. Language: en-us Genres: Life Sciences, Science, Technology Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Episode #128 | Biotools Can Beat Moonshots with Jim West
Episode 128
Sunday, 27 September, 2026
Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator's own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded.Show notesYouTube RecordingSend us Fan MailSupport the showSubscribe to our premium version and support the show. Follow us: Twitter Instagram Linkedin 3DHEALS WebsiteFacebookFacebook GroupYoutube channelAbout Pitch3D
